Search Results

You searched for : Lynparza

	LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Treatments in BRCA1/2-Mutated Advanced Prostate Cancer... Jun 24
	Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer ... Jun 24
	LYNPARZA (olaparib) Receives Three New Approvals in Japan LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.... Dec 28
	LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Only PARP Inhibitor to Demonstrate Overall Survival Versus New Hormonal Agent Treatments in BRCA1/2-Mutated mCRPC... Nov 05
	Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer... Nov 05
	DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer AstraZeneca's patented olaparib for ovary and breast cancer now in India... Aug 20
	Positive About COVID-19 Vaccine, Says UK Pharma Firm AstraZeneca has already reached deals with countries to make more than 2 billion doses of its COVID-19 vaccine with Oxford Univeristy ... Jul 31
	AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate among the most common cancers. ... Jul 08
8 Matching result(s) found!

-Advertisements-

Trending Now
	Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
	Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
	Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
	Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
	Top 5 online learning platform for learnersApril 17, 2024
	Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
	The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
	Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024
	CarDekho's CSR Arm Girnar Foundation Hosts Health Check-up Camps for Underprivileged Children in Jaipur and GurugramApril 16, 2024
	Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 16, 2024
	AVEKSHA, four-day care centres, for the kids of industrial workers inauguratedApril 16, 2024
	Nearly a third of the constituencies have zero women candidates in Phase 1 and 2 of LS Elections; reveals The Quantum Hub’s Factsheet April 16, 2024
	Emergency Healthcare Provider Medulance Secures $3 Million Series A Funding Led by Alkemi Growth CapitalApril 16, 2024
	The Healing Power of Natural Diversity: How Nature Boosts Mental HealthApril 16, 2024
	Unveiling Cellular Recycling: How Nutrient-Starved Cells Adapt to Stressful ConditionsApril 16, 2024
	Advancing Cancer Care: AIIMS Bhopal’s Workshop on Biomarker Interpretation in Breast CancerApril 15, 2024
	10 Powerful Benefits to Diversify Healthcare Advertising ChannelsApril 15, 2024
	Understanding Hospital Sink Contamination: Challenges in Fighting Multidrug-Resistant BacteriaApril 15, 2024
	Rajasthan’s Swine Flu Situation: Health Department Observes DeclineApril 15, 2024
	Is Your Doctor’s Prescription Incomplete ? Insights from Recent ICMR Study Suggests So!April 13, 2024

Search Results

LYNPARZA (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA (olaparib) Receives Three New Approvals in Japan

LYNPARZA Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

DCGI approves AstraZeneca Olaparib tablets for ovarian and breast cancer

Positive About COVID-19 Vaccine, Says UK Pharma Firm

AstraZeneca-Merckâ€™s Lynparza wins EU approval for pancreatic cancer

Trending Now